Latest On China Biologic Products Holdings, Inc (CBPO):
| Date/Time | Type | Description | Signal | Details |
|---|---|---|---|---|
| 2021-04-20 21:13 EST | News | China Biologic Products gains on Nasdaq delisting notice for take private | N/A |  |
| 2021-03-30 03:26 EST | News | China Biologic Products EPS beats by $0.22 | N/A | |
| 2020-12-13 03:27 EST | Financials | Company financials have been released. | Neutral | |
| 2020-11-28 03:25 EST | Financials | Company financials have been released. | Neutral | |
| 2020-11-27 11:29 EST | Analyst Rating | The Analyst Target Price has increased from $101.78 to $102.78. | Neutral | |
| 2020-11-27 03:22 EST | Financials | Company financials have been released. | Neutral | |
| 2020-11-26 20:09 EST | News | China Biologic Products Holdings, Inc. (CBPO) CEO Joseph Chow on Q3 2020 Results - Earnings Call Transcript | N/A | |
| 2020-11-25 19:52 EST | News | China Biologic Products EPS beats by $0.12 | N/A | |
| 2020-11-25 19:51 EST | News | China Biologic Products Holdings, Inc. 2020 Q3 - Results - Earnings Call Presentation | N/A | |
| 2020-11-25 11:33 EST | Earnings Estimate | An EPS average of $1.35 is estimated for the quarter ending on March 31, 2021. | Sell | |
| 2020-11-19 13:36 EST | News | China Biologic inks merger agreement for going private transaction | N/A | |
| 2020-11-15 11:33 EST | Financials | Company financials have been released. | Neutral | |
| 2020-11-01 17:27 EST | Financials | Company financials have been released. | Neutral | |
| 2020-09-24 00:24 EST | Financials | Company financials have been released. | Neutral | |
| 2020-09-19 08:27 EST | Financials | Company financials have been released. | Neutral | |
| 2020-08-19 08:28 EST | News | Update on China Biologic Products Q2 earnings | N/A | |
| 2020-08-19 08:28 EST | News | China Biologic Products Holdings, Inc. (CBPO) CEO Joseph Chow on Q2 2020 Results - Earnings Call Transcript | N/A | |
| 2020-08-19 00:21 EST | Financials | Company financials have been released. | Neutral | |
| 2020-08-18 04:05 EST | News | China Biologic Products EPS misses by $0.17 | N/A | |
| 2020-08-10 12:22 EST | Analyst Rating | The Analyst Target Price has increased from $96.22 to $101.78. | Neutral | |
| 2020-07-31 00:28 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-23 16:32 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-10 08:21 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-01 08:17 EST | Financials | Company financials have been released. | Neutral | |
| 2020-06-02 04:22 EST | Earnings Estimate | An EPS average of $1.21 is estimated for the quarter ending on September 30, 2020. | Sell | |
| 2020-05-31 16:49 EST | Financials | Company financials have been released. | Neutral | |
| 2020-05-24 00:18 EST | Financials | Company financials have been released. | Neutral | |
| 2020-05-22 06:57 EST | News | China Biologic Products EPS beats by $0.18 | N/A | |
| 2020-05-22 06:56 EST | News | China Biologic Products Holdings, Inc. 2020 Q1 - Results - Earnings Call Presentation | N/A | |
| 2020-05-22 06:56 EST | News | China Biologic Products Holdings, Inc. (CBPO) CEO Joseph Chow on Q1 2020 Results - Earnings Call Transcript | N/A | |
| 2020-05-03 08:24 EST | Financials | Company financials have been released. | Neutral | |
| 2020-04-11 06:24 EST | News | China Biologic Products reports Q4 results | N/A | |
| 2020-04-07 04:19 EST | Analyst Rating | The Analyst Target Price has increased from $93.62 to $96.22. | Neutral | |
| 2020-04-07 00:27 EST | Financials | Company financials have been released. | Neutral | |
| 2020-04-01 20:16 EST | Earnings Estimate | An EPS average of $1.39 is estimated for the quarter ending on June 30, 2020. | Buy | |
| 2020-04-01 20:16 EST | Earnings Estimate | An EPS average of $5.09 is estimated for the 2021 year. | Buy | |
| 2020-03-24 04:17 EST | Analyst Rating | The Analyst Target Price has increased from $88.28 to $93.62. | Neutral | |
| 2020-03-14 00:21 EST | Financials | Company financials have been released. | Neutral | |
| 2020-03-13 23:32 EST | News | China Biologic Products Holdings, Inc. (CBPO) CEO Joseph Chow on Q4 2019 Results - Earnings Call Transcript | N/A | |
| 2020-03-13 23:32 EST | News | China Biologic Products Holdings, Inc. 2019 Q4 - Results - Earnings Call Presentation | N/A | |
| 2020-03-11 04:18 EST | Analyst Rating | The Analyst Target Price has increased from $88.22 to $88.28. | Neutral | |
| 2020-02-28 23:20 EST | Financials | Company financials have been released. | Neutral | |
| 2020-02-28 03:22 EST | Financials | Company financials have been released. | Neutral | |
| 2020-02-21 23:16 EST | Financials | Company financials have been released. | Neutral | |
| 2020-02-06 23:18 EST | Financials | Company financials have been released. | Neutral | |
| 2020-01-29 23:19 EST | Financials | Company financials have been released. | Neutral | |
| 2020-01-28 03:23 EST | Earnings | Earnings have been released on March 7, 2019, with $0.89 earnings per share. | Buy | |
| 2020-01-27 23:16 EST | Financials | Company financials have been released. | Neutral | |
| 2020-01-15 23:17 EST | Financials | Company financials have been released. | Neutral | |
| 2020-01-06 03:13 EST | Analyst Rating | The Analyst Target Price has decreased from $91.3 to $88.22. | Sell | |
About China Biologic Products Holdings, Inc (CBPO):
China Biologic Products Holdings, Inc. engages in the research, development, manufacture, and sale of human plasma-based biopharmaceutical products to hospitals and inoculation centers in the People's Republic of China. It offers human albumin for treating shock caused by blood loss trauma or burn; raised intracranial pressure caused by hydrocephalus or trauma; oedema or ascites caused by hepatocirrhosis and nephropathy; and neonatal hyperbilirubinemia, as well as for the prevention and treatment of low-density-lipoproteinemia. The company also provides human immunoglobulin and IVIG for original and secondary immunoglobulin deficiency, auto-immune deficiency, and immunoglobulin G secondary deficiency; human hepatitis B immunoglobulin for the prevention of measles and contagious hepatitis; human rabies immunoglobulin primarily for passive immunity from bites or claws by rabies or other infected animals; and human tetanus immunoglobulin for the prevention and therapy of tetanus. In addition, it offers placenta polypeptide for the treatment of cell immunity deficiency diseases, viral infection, and leucopenia, as well as assists in postoperative healing; factor VIII for treating coagulopathies; human fibrinogen; and human prothrombin complex concentrate for treating congenital and acquired clotting factor II, VII, IX, X deficiency, as well as excessive anticoagulant, vitamin K deficiency, etc. Further, the company is developing Human fibrinogen for the treatment for lack of fibrinogen and increase human fibrinogen concentration; and artificial dura and spinal dura mater products for use in brain and spinal surgeries. The company sells its products directly, as well as through distributors. The company was formerly known as China Biologic Products, Inc. and changed its name to China Biologic Products Holdings, Inc. in July 2017. China Biologic Products Holdings, Inc. is headquartered in Beijing, the People's Republic of China.
General
- Name China Biologic Products Holdings, Inc
- Symbol CBPO
- Type Common Stock
- Exchange NASDAQ
- Currency USD
- Country USA
- SectorHealthcare
- IndustryBiotechnology
- Full Time Employees 2,246
- Fiscal Year EndDecember
- IPO Date2008-01-29
- Gic SectorHealth Care
- Gic GroupPharmaceuticals, Biotechnology & Life Sciences
- Gic IndustryBiotechnology
- Gic SubIndustryBiotechnology
- Web URLhttp://www.chinabiologic.com
View More
Valuation
- Trailing PE 32.91
- Forward PE 21.19
- Price/Sales (Trailing 12 Mt.) 9.15
- Price/Book (Most Recent Quarter) 2.4
- Enterprise Value Revenue 6.67
- Enterprise Value EBITDA 15.19
View More
Financials
- Most Recent Quarter 2020-09-30
- Next Quarter EPS Estimate $0.69
- Profit Margin 27%
- Operating Margin 35%
- Return on Assets 6%
- Return on Equity 9%
- Revenue 514.4 million
- Earnings Per Share $3.57
- Revenue Per Share $13.35
- Gross Profit 329.08 million
- Quarterly Earnings Growth 1.8%
View More
Highlights
- Market Capitalization 4.56 billion
- EBITDA 208.59 million
- PEG Ratio 1.53
- Analyst Target Price $102.78
- Book Value Per Share $48.63
View More
Share Statistics
- Shares Outstanding 38.79 million
- Shares Float 13.05 million
- % Held by Insiders 4559%
- % Held by Institutions 50.29%
- Shares Short 904687
- Shares Short Prior Month 978972
- Short Ratio 4.02
- Short % of Float 4%
- Short % of Shares Outstanding 2%
View More
Technicals
- Beta 0.42
- 52 Week High $120.01
- 52 Week Low $97.91
- 50 Day Moving Average 118.36
- 200 Day Moving Average 115.79
View More
Dividends
- Dividend Date N/A
- ExDividend Date N/A
- Dividend Yield 0%
View More
China Biologic Products Holdings, Inc (CBPO) Dividend Calendar:
| Ex-Dividend Date | Payment Date | Record Date | Declared Date | Amount |
|---|
China Biologic Products Holdings, Inc (CBPO) Earnings History:
Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.
| Quarter Date | Report Date | Actual Revenue | Reported EPS | EPS Estimate | Deviation from Estimate |
|---|---|---|---|---|---|
| 2020-09-30 | 2020-11-24 | $138.54 million | $1.39 | $1.28 | 8.59% |
| 2020-06-30 | 2020-08-17 | $N/A | $1.11 | $1.28 | -13.28% |
| 2020-03-31 | 2020-05-20 | $162.59 million | $1.56 | $1.38 | 13.04% |
| 2019-12-31 | 2020-03-12 | $102.16 million | $0.53 | $0.70 | -24.29% |
| 2019-09-30 | 2019-11-13 | $136.11 million | $1.40 | $0.88 | 59.09% |
| 2019-06-30 | 2019-08-05 | $135.7 million | $1.24 | $1.03 | 20.39% |
| 2019-03-31 | 2019-05-10 | $129.78 million | $1.11 | $0.99 | 12.69% |
| 2018-12-31 | 2019-03-06 | $114.93 million | $0.76 | $0.63 | 20.63% |
| 2018-09-30 | 2018-11-01 | $119.11 million | $0.96 | $0.97 | -0.72% |
| 2018-06-30 | 2018-08-03 | $120.38 million | $1.17 | $1.24 | -5.26% |
| 2018-03-31 | 2018-05-04 | $112.46 million | $1.21 | $1.28 | -5.47% |
| 2017-12-31 | 2018-02-28 | $90.12 million | $0.90 | $0.87 | 4.05% |
| 2017-09-30 | 2017-11-01 | $99.56 million | $1.38 | $1.19 | 16.46% |
| 2017-06-30 | 2017-08-02 | $89.28 million | $1.35 | $1.30 | 4.25% |
| 2017-03-31 | 2017-05-03 | $91.45 million | $1.32 | $1.24 | 6.45% |
| 2016-12-31 | 2017-02-23 | $77.63 million | $0.95 | $0.84 | 13.1% |
| 2016-09-30 | 2016-11-02 | $86.53 million | $1.22 | $1.05 | 16.19% |
| 2016-06-30 | 2016-08-04 | $91.42 million | $1.26 | $1.16 | 8.62% |
| 2016-03-31 | 2016-05-04 | $85.59 million | $1.09 | ||
| 2015-12-31 | 2016-02-25 | $68.29 million | $0.59 | $0.55 | 7.27% |
| 2015-09-30 | 2015-11-03 | $78.75 million | $0.82 | $0.81 | 1.23% |
| 2015-06-30 | 2015-08-05 | $79.07 million | $0.99 | $0.87 | 13.79% |
| 2015-03-31 | 2015-05-06 | $70.35 million | $0.87 | $0.84 | 3.57% |
| 2014-12-31 | 2015-03-04 | $57.99 million | $0.48 | $0.51 | -5.88% |
| 2014-09-30 | 2014-11-05 | $68.92 million | $0.76 | $0.64 | 18.75% |
| 2014-06-30 | 2014-08-05 | $60.07 million | $0.79 | $0.67 | 17.91% |
| 2014-03-31 | 2014-05-07 | $56.27 million | $0.69 | ||
| 2013-12-31 | 2014-03-12 | $42.59 million | $0.32 | $0.38 | -15.79% |
| 2013-09-30 | 2013-11-05 | $53.15 million | $0.56 | $0.42 | 33.33% |
| 2013-06-30 | 2013-08-06 | $53.58 million | $0.62 | $0.48 | 29.17% |
| 2013-03-31 | 2013-05-08 | $54.03 million | $0.59 | $0.46 | 28.26% |
| 2012-12-31 | 2013-03-13 | $34 million | $0.21 | $0.18 | 16.67% |
| 2012-09-30 | 2012-11-09 | $53.12 million | $0.50 | ||
| 2012-06-30 | 2012-08-10 | $50.47 million | $0.46 | ||
| 2012-03-31 | 2012-05-08 | $47.23 million | $0.44 | ||
| 2011-12-31 | 2012-03-12 | $35.65 million | $0.29 | ||
| 2011-09-30 | 2011-11-07 | $41.3 million | -$0.37 | ||
| 2011-06-30 | 2011-08-09 | $41.67 million | $0.28 | ||
| 2011-03-31 | 2011-05-09 | $34.47 million | $0.23 | $0.26 | -11.54% |
| 2010-12-31 | 2011-03-31 | $35.68 million | -$0.19 | $0.39 | -148.72% |
| 2010-09-30 | 2010-11-15 | $36 million | $0.53 | $0.32 | 65.63% |
| 2010-06-30 | 2010-08-16 | $40.91 million | $0.49 | $0.36 | 36.11% |
| 2010-03-31 | 2010-05-17 | $27.1 million | $0.41 | $0.28 | 46.43% |
| 2009-12-31 | 2010-03-23 | $37.63 million | -$0.17 | $0.24 | -170.83% |
| 2009-09-30 | 2009-11-16 | $27.04 million | -$0.29 | ||
| 2009-06-30 | 2009-08-17 | $33.18 million | $0.32 | ||
| 2009-03-31 | 2009-05-18 | $21.15 million | $0.20 | ||
| 2008-09-30 | 2008-11-12 | $13.8 million | $0.21 | ||
| 2008-06-30 | 2008-09-03 | $11.93 million | $0.09 | ||
| 2008-03-31 | 2008-03-31 | $7.85 million | $0.10 | ||
| 2007-09-30 | 2007-09-30 | $8.94 million | $0.11 | ||
| 2007-06-30 | 2007-06-30 | $8.83 million | $0.25 |
China Biologic Products Holdings, Inc (CBPO) Company Financial Statements:
Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.
Income Statement:
| Date | Sep 30 2020 | Jun 30 2020 | Mar 31 2020 | Dec 31 2019 | Sep 30 2019 |
|---|---|---|---|---|---|
| Research Development | 1.17 million | N/A | 1.74 million | 4.28 million | 2.69 million |
| Income Before Tax | 56.13 million | N/A | 73.86 million | 20.99 million | 61.17 million |
| Selling General Administrative | 39.28 million | N/A | 31.22 million | 41.11 million | 32.96 million |
| Gross Profit | 92.47 million | N/A | 100.99 million | 63.99 million | 88.64 million |
| Ebit | 63.02 million | N/A | 80.59 million | 18.6 million | 52.99 million |
| Operating Income | 52.02 million | N/A | 68.03 million | 18.6 million | 52.99 million |
| Income Tax Expense | N/A | 6.6 million | 11.62 million | 4.39 million | 7.63 million |
| Total Revenue | 138.54 million | N/A | 162.59 million | 102.16 million | 136.11 million |
| Cost of Revenue | 46.07 million | N/A | 61.6 million | 38.17 million | 47.47 million |
| Total Other Income Expense Net | 3.7 million | N/A | 1.41 million | 2.39 million | 8.17 million |
| Net Income From Continuing Operations | 46.42 million | N/A | 62.23 million | 16.6 million | 53.54 million |
| Net Income Applicable to Common Shares | N/A | 35.68 million | 53.38 million | 12.45 million | 47.02 million |
Cash Flow:
| Date | Sep 30 2020 | Jun 30 2020 | Mar 31 2020 | Dec 31 2019 | Sep 30 2019 |
|---|---|---|---|---|---|
| Investments | -27.77 million | N/A | -113.44 million | -142.32 million | 84.42 million |
| Change to Liabilities | N/A | 3.51 million | -543228 | 840643 | 2.12 million |
| Total Cash Flow from Investing Activities | N/A | 369.5 million | -113.44 million | -142.52 million | 79.87 million |
| Net Borrowings | N/A | N/A | N/A | N/A | N/A |
| Total Cash Flow from Financial Activities | -4.98 million | N/A | N/A | 9.19 million | -123.79 million |
| Change to Operating Activities | N/A | 5.55 million | -5.75 million | 4.13 million | -230957 |
| Change in Cash | 21.72 million | N/A | -38.89 million | -59.1 million | 18.4 million |
| Total Cash from Operating Activities | 53.02 million | 59.73 million | 75.74 million | 72.92 million | 62.2 million |
| Depreciation | 6.81 million | N/A | 6.63 million | 7.25 million | 6.48 million |
| Other Cash Flow from Investing Activities | N/A | N/A | N/A | N/A | N/A |
| Change to Inventory | 49779 | N/A | 32.96 million | -5.97 million | -4.57 million |
| Change to Account Receivables | -16.26 million | N/A | -35.26 million | 41.36 million | -3.99 million |
| Other Cash Flow from Financing Activities | N/A | -7.3 million | N/A | 9.03 million | -124.01 million |
| Change to Net Income | N/A | 10.59 million | 16.26 million | 15.55 million | 13.73 million |
| Capital Expenditures | 7.08 million | N/A | 3.24 million | 5.47 million | 6.09 million |
Balance Sheet:
| Date | Sep 30 2020 | Jun 30 2020 | Mar 31 2020 | Dec 31 2019 | Sep 30 2019 |
|---|---|---|---|---|---|
| Total Liabailities | N/A | N/A | 174.26 million | 163.01 million | 160.4 million |
| Total Stockholder Equity | N/A | N/A | 1.74 billion | 1.7 billion | 1.66 billion |
| Other Current Liabilities | 117.48 million | N/A | N/A | 113.05 million | 114.9 million |
| Total Assets | N/A | N/A | 1.98 billion | 1.94 billion | 1.89 billion |
| Common Stock | 4224 | 4203 | 4193 | 4191 | 4190 |
| Other Current Assets | 21.01 million | N/A | N/A | 21.47 million | 33.45 million |
| Retained Earnings | 901.9 million | 862.36 million | 826.67 million | 773.29 million | 760.84 million |
| Other Liabilities | 39.38 million | 41.44 million | 44.9 million | 43.7 million | 40.17 million |
| Other Assets | 52.93 million | 51.78 million | 51.82 million | 51.96 million | 47.9 million |
| Cash | N/A | N/A | 122.86 million | 161.75 million | 220.85 million |
| Total Current Liabilities | 124.45 million | N/A | 129.36 million | 119.31 million | 120.23 million |
| Other Stockholder Equity | -35.8 million | -87.47 million | -88.47 million | -68.42 million | -83.58 million |
| Property, Plant & Equipment | 180.06 million | 172.37 million | 173.33 million | 177.6 million | 176.18 million |
| Total Current Assets | 1.49 billion | N/A | 1.36 billion | 1.3 billion | 1.26 billion |
| Long Term Investments | N/A | N/A | 26.51 million | 27.54 million | 27.37 million |
| Net Tangible Assets | 1.5 billion | 1.41 billion | 1.36 billion | 1.31 billion | 1.28 billion |
| Short Term Investments | N/A | N/A | 868.78 million | 765.51 million | 620.51 million |
| Long Term Debt | N/A | N/A | N/A | N/A | N/A |
| Inventory | 234.47 million | N/A | 214.44 million | 250.73 million | 243.85 million |
| Accounts Payable | 6.97 million | N/A | 5.75 million | 6.26 million | 5.34 million |
China Biologic Products Holdings, Inc (CBPO) Chart:
China Biologic Products Holdings, Inc (CBPO) News:
Below you will find a list of latest news for China Biologic Products Holdings, Inc (CBPO) from major news sources. You can filter the results to only show news from a specific source.
No recent news available
China Biologic Products Holdings, Inc (CBPO) Options:
A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.
| Expiration Date | Strike | Last Price | Type | Volume | Open Interest | Implied Volatility | In The Money | Change | Change Percent |
|---|
China Biologic Products Holdings, Inc (CBPO) SEC Filings:
An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.
| Date | Form Type | Form Name | Link |
|---|---|---|---|
| 2020-06-29 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1369868/000110465920077738/0001104659-20-077738-index.htm |
| 2018-02-13 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1369868/000031506618001126/0000315066-18-001126-index.htm |
| 2018-02-14 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1369868/000085874418000012/0000858744-18-000012-index.htm |
| 2018-02-12 | SC 13G | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1369868/000089843218000186/0000898432-18-000186-index.htm |
| 2019-02-12 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1369868/000089843219000205/0000898432-19-000205-index.htm |
| 2019-09-27 | SC 13D | General statement of acquisition of beneficial ownership | https://www.sec.gov/Archives/edgar/data/1369868/000089843219001206/0000898432-19-001206-index.htm |
| 2019-11-06 | SC 13D/A | General statement of acquisition of beneficial ownership | https://www.sec.gov/Archives/edgar/data/1369868/000089843219001297/0000898432-19-001297-index.htm |
| 2020-03-20 | SC 13D/A | General statement of acquisition of beneficial ownership | https://www.sec.gov/Archives/edgar/data/1369868/000089843220000377/0000898432-20-000377-index.htm |
| 2020-04-14 | SC 13D/A | General statement of acquisition of beneficial ownership | https://www.sec.gov/Archives/edgar/data/1369868/000089843220000490/0000898432-20-000490-index.htm |
| 2020-09-17 | SC 13D/A | General statement of acquisition of beneficial ownership | https://www.sec.gov/Archives/edgar/data/1369868/000089843220000780/0000898432-20-000780-index.htm |
| 2020-10-28 | SC 13D/A | General statement of acquisition of beneficial ownership | https://www.sec.gov/Archives/edgar/data/1369868/000089843220000832/0000898432-20-000832-index.htm |
| 2018-09-04 | SC 13G | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1369868/000090266418003339/0000902664-18-003339-index.htm |
| 2019-02-14 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1369868/000090266419001102/0000902664-19-001102-index.htm |
| 2019-09-19 | SC 13D | General statement of acquisition of beneficial ownership | https://www.sec.gov/Archives/edgar/data/1369868/000090266419003770/0000902664-19-003770-index.htm |
| 2020-01-27 | SC 13D/A | General statement of acquisition of beneficial ownership | https://www.sec.gov/Archives/edgar/data/1369868/000090266420000488/0000902664-20-000488-index.htm |
| 2020-05-08 | SC 13D/A | General statement of acquisition of beneficial ownership | https://www.sec.gov/Archives/edgar/data/1369868/000090266420002022/0000902664-20-002022-index.htm |
| 2020-09-18 | SC 13D/A | General statement of acquisition of beneficial ownership | https://www.sec.gov/Archives/edgar/data/1369868/000090266420003366/0000902664-20-003366-index.htm |
| 2020-10-28 | SC 13D/A | General statement of acquisition of beneficial ownership | https://www.sec.gov/Archives/edgar/data/1369868/000090266420003758/0000902664-20-003758-index.htm |
| 2018-12-18 | SC 13D/A | General statement of acquisition of beneficial ownership | https://www.sec.gov/Archives/edgar/data/1369868/000095010318014719/0000950103-18-014719-index.htm |
| 2019-01-08 | SC 13D/A | General statement of acquisition of beneficial ownership | https://www.sec.gov/Archives/edgar/data/1369868/000095010319000310/0000950103-19-000310-index.htm |
| 2019-02-04 | SC 13D/A | General statement of acquisition of beneficial ownership | https://www.sec.gov/Archives/edgar/data/1369868/000095010319001572/0000950103-19-001572-index.htm |
| 2019-03-12 | SC 13D/A | General statement of acquisition of beneficial ownership | https://www.sec.gov/Archives/edgar/data/1369868/000095010319003298/0000950103-19-003298-index.htm |
| 2018-02-14 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1369868/000107333018000006/0001073330-18-000006-index.htm |
| 2017-10-10 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1369868/000108887517000059/0001088875-17-000059-index.htm |
| 2019-10-17 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1369868/000110465919054506/0001104659-19-054506-index.htm |
| 2019-11-13 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1369868/000110465919063391/0001104659-19-063391-index.htm |
| 2019-11-18 | SC 13D/A | General statement of acquisition of beneficial ownership | https://www.sec.gov/Archives/edgar/data/1369868/000110465919064932/0001104659-19-064932-index.htm |
| 2020-01-24 | SC 13D/A | General statement of acquisition of beneficial ownership | https://www.sec.gov/Archives/edgar/data/1369868/000110465920006462/0001104659-20-006462-index.htm |
| 2020-01-24 | SC 13D/A | General statement of acquisition of beneficial ownership | https://www.sec.gov/Archives/edgar/data/1369868/000110465920006484/0001104659-20-006484-index.htm |
| 2020-01-24 | SC 13D/A | General statement of acquisition of beneficial ownership | https://www.sec.gov/Archives/edgar/data/1369868/000110465920006492/0001104659-20-006492-index.htm |
| 2020-02-19 | SC 13E3/A | Going private transaction by certain issuers | https://www.sec.gov/Archives/edgar/data/1369868/000110465920022796/0001104659-20-022796-index.htm |
| 2020-03-12 | 20-F | Annual and transition report of foreign private issuers [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1369868/000110465920032518/0001104659-20-032518-index.htm |
| 2020-03-12 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1369868/000110465920032579/0001104659-20-032579-index.htm |
| 2020-03-20 | SC 13D/A | General statement of acquisition of beneficial ownership | https://www.sec.gov/Archives/edgar/data/1369868/000110465920036400/0001104659-20-036400-index.htm |
| 2020-03-20 | SC 13D/A | General statement of acquisition of beneficial ownership | https://www.sec.gov/Archives/edgar/data/1369868/000110465920036457/0001104659-20-036457-index.htm |
| 2020-03-30 | SC 13E3/A | Going private transaction by certain issuers | https://www.sec.gov/Archives/edgar/data/1369868/000110465920039960/0001104659-20-039960-index.htm |
| 2020-04-08 | SC 13D/A | General statement of acquisition of beneficial ownership | https://www.sec.gov/Archives/edgar/data/1369868/000110465920044714/0001104659-20-044714-index.htm |
| 2020-04-10 | SC 13D/A | General statement of acquisition of beneficial ownership | https://www.sec.gov/Archives/edgar/data/1369868/000110465920045389/0001104659-20-045389-index.htm |
| 2020-04-24 | SC 13E3/A | Going private transaction by certain issuers | https://www.sec.gov/Archives/edgar/data/1369868/000110465920050713/0001104659-20-050713-index.htm |
| 2020-05-01 | SC 13D/A | General statement of acquisition of beneficial ownership | https://www.sec.gov/Archives/edgar/data/1369868/000110465920055013/0001104659-20-055013-index.htm |
| 2020-05-05 | SC 13D/A | General statement of acquisition of beneficial ownership | https://www.sec.gov/Archives/edgar/data/1369868/000110465920056574/0001104659-20-056574-index.htm |
| 2020-05-07 | SC 13D/A | General statement of acquisition of beneficial ownership | https://www.sec.gov/Archives/edgar/data/1369868/000110465920057789/0001104659-20-057789-index.htm |
| 2020-05-08 | S-8 | Securities to be offered to employees in employee benefit plans | https://www.sec.gov/Archives/edgar/data/1369868/000110465920058842/0001104659-20-058842-index.htm |
| 2020-05-11 | SC 13D/A | General statement of acquisition of beneficial ownership | https://www.sec.gov/Archives/edgar/data/1369868/000110465920059145/0001104659-20-059145-index.htm |
| 2020-05-20 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1369868/000110465920064316/0001104659-20-064316-index.htm |
| 2020-06-29 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1369868/000110465920077738/0001104659-20-077738-index.htm |
| 2020-08-17 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1369868/000110465920096148/0001104659-20-096148-index.htm |
| 2020-09-17 | SC 13D/A | General statement of acquisition of beneficial ownership | https://www.sec.gov/Archives/edgar/data/1369868/000110465920105926/0001104659-20-105926-index.htm |
| 2020-09-17 | SC 13D/A | General statement of acquisition of beneficial ownership | https://www.sec.gov/Archives/edgar/data/1369868/000110465920105937/0001104659-20-105937-index.htm |
| 2020-09-17 | SC 13D/A | General statement of acquisition of beneficial ownership | https://www.sec.gov/Archives/edgar/data/1369868/000110465920105941/0001104659-20-105941-index.htm |
| 2020-09-23 | SC 13D | General statement of acquisition of beneficial ownership | https://www.sec.gov/Archives/edgar/data/1369868/000110465920107498/0001104659-20-107498-index.htm |
| 2020-10-28 | SC 13D/A | General statement of acquisition of beneficial ownership | https://www.sec.gov/Archives/edgar/data/1369868/000110465920118751/0001104659-20-118751-index.htm |
| 2020-10-28 | SC 13D/A | General statement of acquisition of beneficial ownership | https://www.sec.gov/Archives/edgar/data/1369868/000110465920118753/0001104659-20-118753-index.htm |
| 2020-10-28 | SC 13D/A | General statement of acquisition of beneficial ownership | https://www.sec.gov/Archives/edgar/data/1369868/000110465920118756/0001104659-20-118756-index.htm |
| 2020-10-29 | SC 13D/A | General statement of acquisition of beneficial ownership | https://www.sec.gov/Archives/edgar/data/1369868/000110465920119144/0001104659-20-119144-index.htm |
| 2019-09-30 | SC 13D | General statement of acquisition of beneficial ownership | https://www.sec.gov/Archives/edgar/data/1369868/000114036119017530/0001140361-19-017530-index.htm |
| 2020-01-24 | SC 13D/A | General statement of acquisition of beneficial ownership | https://www.sec.gov/Archives/edgar/data/1369868/000114036120001388/0001140361-20-001388-index.htm |
| 2020-09-18 | SC 13D/A | General statement of acquisition of beneficial ownership | https://www.sec.gov/Archives/edgar/data/1369868/000114036120020820/0001140361-20-020820-index.htm |
| 2017-08-02 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1369868/000114420417039925/0001144204-17-039925-index.htm |
| 2017-08-02 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1369868/000114420417040005/0001144204-17-040005-index.htm |
| 2017-08-03 | 8-A12B/A | Registration of securities [Section 12(b)] | https://www.sec.gov/Archives/edgar/data/1369868/000114420417040336/0001144204-17-040336-index.htm |
| 2017-10-10 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1369868/000114420417051728/0001144204-17-051728-index.htm |
| 2017-10-13 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1369868/000114420417052328/0001144204-17-052328-index.htm |
| 2017-11-01 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1369868/000114420417055529/0001144204-17-055529-index.htm |
| 2017-12-15 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1369868/000114420417063829/0001144204-17-063829-index.htm |
| 2017-12-29 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1369868/000114420417065699/0001144204-17-065699-index.htm |
| 2018-01-03 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1369868/000114420418000340/0001144204-18-000340-index.htm |
| 2018-01-08 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1369868/000114420418001203/0001144204-18-001203-index.htm |
| 2018-01-10 | SC 13D | General statement of acquisition of beneficial ownership | https://www.sec.gov/Archives/edgar/data/1369868/000114420418001565/0001144204-18-001565-index.htm |
| 2018-02-14 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1369868/000114420418008299/0001144204-18-008299-index.htm |
| 2018-02-28 | 20-F | Annual and transition report of foreign private issuers [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1369868/000114420418011790/0001144204-18-011790-index.htm |
| 2018-02-28 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1369868/000114420418011834/0001144204-18-011834-index.htm |
| 2018-04-24 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1369868/000114420418021951/0001144204-18-021951-index.htm |
| 2018-05-04 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1369868/000114420418025437/0001144204-18-025437-index.htm |
| 2018-05-07 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1369868/000114420418025751/0001144204-18-025751-index.htm |
| 2018-06-11 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1369868/000114420418033660/0001144204-18-033660-index.htm |
| 2018-06-18 | SC 13D | General statement of acquisition of beneficial ownership | https://www.sec.gov/Archives/edgar/data/1369868/000114420418034488/0001144204-18-034488-index.htm |
| 2018-06-19 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1369868/000114420418034717/0001144204-18-034717-index.htm |
| 2018-07-02 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1369868/000114420418036814/0001144204-18-036814-index.htm |
| 2018-07-09 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1369868/000114420418037609/0001144204-18-037609-index.htm |
| 2018-07-12 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1369868/000114420418038054/0001144204-18-038054-index.htm |
| 2018-07-25 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1369868/000114420418039751/0001144204-18-039751-index.htm |
| 2018-08-03 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1369868/000114420418041953/0001144204-18-041953-index.htm |
| 2018-08-13 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1369868/000114420418043731/0001144204-18-043731-index.htm |
| 2018-08-20 | SC 13D | General statement of acquisition of beneficial ownership | https://www.sec.gov/Archives/edgar/data/1369868/000114420418045448/0001144204-18-045448-index.htm |
| 2018-08-20 | SC 13D | General statement of acquisition of beneficial ownership | https://www.sec.gov/Archives/edgar/data/1369868/000114420418045449/0001144204-18-045449-index.htm |
| 2018-08-21 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1369868/000114420418045699/0001144204-18-045699-index.htm |
| 2018-08-24 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1369868/000114420418046156/0001144204-18-046156-index.htm |
| 2018-08-27 | SC 13D/A | General statement of acquisition of beneficial ownership | https://www.sec.gov/Archives/edgar/data/1369868/000114420418046349/0001144204-18-046349-index.htm |
| 2018-08-27 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1369868/000114420418046354/0001144204-18-046354-index.htm |
| 2018-08-27 | SC 13D/A | General statement of acquisition of beneficial ownership | https://www.sec.gov/Archives/edgar/data/1369868/000114420418046359/0001144204-18-046359-index.htm |
| 2018-08-28 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1369868/000114420418046753/0001144204-18-046753-index.htm |
| 2018-09-04 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1369868/000114420418047818/0001144204-18-047818-index.htm |
| 2018-09-14 | SC 13D | General statement of acquisition of beneficial ownership | https://www.sec.gov/Archives/edgar/data/1369868/000114420418049406/0001144204-18-049406-index.htm |
| 2018-09-21 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1369868/000114420418050371/0001144204-18-050371-index.htm |
| 2018-09-24 | SC 13D/A | General statement of acquisition of beneficial ownership | https://www.sec.gov/Archives/edgar/data/1369868/000114420418050458/0001144204-18-050458-index.htm |
| 2018-10-16 | SC 13D/A | General statement of acquisition of beneficial ownership | https://www.sec.gov/Archives/edgar/data/1369868/000114420418053916/0001144204-18-053916-index.htm |
| 2018-10-31 | SC 13D/A | General statement of acquisition of beneficial ownership | https://www.sec.gov/Archives/edgar/data/1369868/000114420418056273/0001144204-18-056273-index.htm |
| 2018-11-01 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1369868/000114420418056832/0001144204-18-056832-index.htm |
| 2018-11-19 | SC 13D/A | General statement of acquisition of beneficial ownership | https://www.sec.gov/Archives/edgar/data/1369868/000114420418060599/0001144204-18-060599-index.htm |
| 2018-12-14 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1369868/000114420418064551/0001144204-18-064551-index.htm |
| 2019-01-07 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1369868/000114420419000779/0001144204-19-000779-index.htm |
| 2019-02-04 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1369868/000114420419004520/0001144204-19-004520-index.htm |
| 2019-02-20 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1369868/000114420419009113/0001144204-19-009113-index.htm |
| 2019-02-20 | 8-A12B/A | Registration of securities [Section 12(b)] | https://www.sec.gov/Archives/edgar/data/1369868/000114420419009120/0001144204-19-009120-index.htm |
| 2019-03-06 | 20-F | Annual and transition report of foreign private issuers [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1369868/000114420419012555/0001144204-19-012555-index.htm |
| 2019-03-06 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1369868/000114420419012588/0001144204-19-012588-index.htm |
| 2019-05-10 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1369868/000114420419025300/0001144204-19-025300-index.htm |
| 2019-05-10 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1369868/000114420419025309/0001144204-19-025309-index.htm |
| 2019-05-15 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1369868/000114420419026611/0001144204-19-026611-index.htm |
| 2019-06-28 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1369868/000114420419033066/0001144204-19-033066-index.htm |
| 2019-08-05 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1369868/000114420419037681/0001144204-19-037681-index.htm |
| 2019-09-19 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1369868/000114420419045132/0001144204-19-045132-index.htm |
| 2019-09-19 | SC 13D/A | General statement of acquisition of beneficial ownership | https://www.sec.gov/Archives/edgar/data/1369868/000114420419045140/0001144204-19-045140-index.htm |
| 2019-09-19 | SC 13D/A | General statement of acquisition of beneficial ownership | https://www.sec.gov/Archives/edgar/data/1369868/000114420419045144/0001144204-19-045144-index.htm |
| 2019-09-20 | SC 13D/A | General statement of acquisition of beneficial ownership | https://www.sec.gov/Archives/edgar/data/1369868/000114420419045332/0001144204-19-045332-index.htm |
| 2019-09-24 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1369868/000114420419045691/0001144204-19-045691-index.htm |
| 2018-02-14 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1369868/000142284818000281/0001422848-18-000281-index.htm |
| 2018-11-09 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1369868/000142284818000410/0001422848-18-000410-index.htm |
| 2019-02-14 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1369868/000142284819000029/0001422848-19-000029-index.htm |
| 2019-09-10 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1369868/000142284819000137/0001422848-19-000137-index.htm |
| 2019-12-10 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1369868/000142284819000143/0001422848-19-000143-index.htm |